Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom
By Reuters Publication Date: 2026-10-08 18:09:00 Oct 8 (Reuters) – Nvidia-backed Iambic Therapeutics, which uses AI to develop drugs, is…
Tag: Therapeutics
Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
By Reuters Publication Date: 2026-10-08 12:08:00 Iambic Therapeutics, which is backed by Nvidia , is aiming to raise as much…
Nvidia-backed AI drugmaker Iambic Therapeutics seeks U.S. listing
By Manshi Mamtora Publication Date: 2026-09-22 04:44:00 Iambic Therapeutics, an AI-driven drug discovery company backed by Nvidia (NVDA), filed for…
Nvidia-Backed AI Drug Startup Iambic Therapeutics Files For IPO
By Radhika Anilkumar Nadig Publication Date: 2026-09-22 02:00:00 Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the…
Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on
By Investing.com Publication Date: 2026-09-21 21:42:00 Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on
Applying multimodal biological foundation models across therapeutics and patient care | Amazon Web Services
Healthcare and life sciences decision making increasingly relies on multimodal data to diagnose diseases, prescribe medicine and predict treatment outcomes,…
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday – Broadcom (NASDAQ:AVGO)
By Avi Kapoor Publication Date: 2026-04-06 05:33:00 With U.S. stock futures trading mixed this morning on Monday, some of the…
BriaCell and Receptor.AI collaborate on AI-driven small molecule cancer therapeutics
By BriaCell Therapeutics Corp. Publication Date: 2025-11-20 12:30:00 BriaCell Therapeutics Corp. The collaboration leverages Receptor AI’s platform to develop highly…
Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D
AZURE-2 evaluates the efficacy and safety of brelovitug as a monotherapy compared head-to-head with Hepcludex (bulevirtide) Enrollment in AZURE-1, a global…
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics – Business Wire
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics Business Wire Article Source https://www.businesswire.com/news/home/20250417061472/en/BigHat-Biosciences-and-Lilly-Collaborate-to-Advance-AI-Driven-Antibody-Therapeutics